CA1326700C - Soluble covering for cardiac pacing electrode - Google Patents
Soluble covering for cardiac pacing electrodeInfo
- Publication number
- CA1326700C CA1326700C CA000585746A CA585746A CA1326700C CA 1326700 C CA1326700 C CA 1326700C CA 000585746 A CA000585746 A CA 000585746A CA 585746 A CA585746 A CA 585746A CA 1326700 C CA1326700 C CA 1326700C
- Authority
- CA
- Canada
- Prior art keywords
- electrode
- covering
- fixation element
- lead
- intravascular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
- A61B5/6852—Catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/25—Bioelectric electrodes therefor
- A61B5/279—Bioelectric electrodes therefor specially adapted for particular uses
- A61B5/28—Bioelectric electrodes therefor specially adapted for particular uses for electrocardiography [ECG]
- A61B5/283—Invasive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/25—Bioelectric electrodes therefor
- A61B5/279—Bioelectric electrodes therefor specially adapted for particular uses
- A61B5/28—Bioelectric electrodes therefor specially adapted for particular uses for electrocardiography [ECG]
- A61B5/283—Invasive
- A61B5/288—Invasive for foetal cardiography, e.g. scalp electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/25—Bioelectric electrodes therefor
- A61B5/279—Bioelectric electrodes therefor specially adapted for particular uses
- A61B5/28—Bioelectric electrodes therefor specially adapted for particular uses for electrocardiography [ECG]
- A61B5/283—Invasive
- A61B5/29—Invasive for permanent or long-term implantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/43—Detecting, measuring or recording for evaluating the reproductive systems
- A61B5/4306—Detecting, measuring or recording for evaluating the reproductive systems for evaluating the female reproductive systems, e.g. gynaecological evaluations
- A61B5/4343—Pregnancy and labour monitoring, e.g. for labour onset detection
- A61B5/4362—Assessing foetal parameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/056—Transvascular endocardial electrode systems
- A61N1/0565—Electrode heads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/056—Transvascular endocardial electrode systems
- A61N1/057—Anchoring means; Means for fixing the head inside the heart
- A61N1/0573—Anchoring means; Means for fixing the head inside the heart chacterised by means penetrating the heart tissue, e.g. helix needle or hook
Abstract
SOLUBLE COVERING FOR CARDIAC PACING ELECTRODE
ABSTRACT OF THE DISCLOSURE
A biocompatible covering, soluble in body fluids, surrounds the fixation helix of an implantable cardiac electrode as the electrode, and its adjoining lead, are inserted intravenously to a selected cardiac chamber. The covering size and shape are selected for protection of blood vessels and other body tissues during insertion, and for exposure of the fixation element shortly after its proper positioning. The covering may be applied to the fixation element by a dip coating process, or formed separately by casting or injection molding, for later attachment to the lead distal end using an adhesive.
ABSTRACT OF THE DISCLOSURE
A biocompatible covering, soluble in body fluids, surrounds the fixation helix of an implantable cardiac electrode as the electrode, and its adjoining lead, are inserted intravenously to a selected cardiac chamber. The covering size and shape are selected for protection of blood vessels and other body tissues during insertion, and for exposure of the fixation element shortly after its proper positioning. The covering may be applied to the fixation element by a dip coating process, or formed separately by casting or injection molding, for later attachment to the lead distal end using an adhesive.
Description
~ 3~ ~7-~
~O~UBLE COVERIN~ FO~ CA~DIAC PACIN~ ELECTRODE
BACKGROUND OF THE INVENTION
This invention relates to cardiac diagnostic and chronic therapeutic leads, and more particularly to fixation leads in which an electrode includes an anchoring element.
The utility of cardiac pacing leads is well recognized, both for carrying pulse stimulation signals ~o the heart from a pacemaker, and for monitoring heart electrical activity from outside the body. Many such leads are sufficiently flexible and small in diameter for intravenous introduction to a cardiac cavity, whereupon an electrode at the distal end of the lead is implanted into the endocardium to secure the lead. For this purpose, helical coils, barbs and other anchoring elements are provided, typically as part of the electrode.
The anchoring element must be sufficiently sharp to penetrate the endocardium and secure the e~ectrode against becoming detached, for example due to contractions of the myocardium. During a critical period immediately aftex implant and prior to full fibrotic growth, usually three to twelve weeks, the anchoring element must provide substantially the entire force maintaining the electrode in its selected location~ Given these requirements, it is not surprising that an effective anchoring alement can become entangled in the vein, heart valve or other tissue encountered during its intravenous insertion.
The problem has given rise to numerous proposed solutions. For example, U. S. Patent No. 3,974,834 to Kane granted August 17, 1976 shows a sleeve which shrouds the sharp tip of a fixation helix, but collapses in accordion-like fashion as the helix is turned into the endocardium. In U. S. Patent No.
30 4,282,885 to Bisping granted August 11, 1981, a protective core l~267~a is surrounded by the helix, and is movable axially relative to the helix. A wire, attached to the core, extends through the lead and can be pulled after lead insertion to withdraw the core, exposing the helix. U. S. Patent No. 4,146,036 to Dutcher et al granted March 27, 1975 discloses an extensible and retractable core surrounded by the helix.
Other solutions involve makiny the fixation element movable. For example, in U. S. Patent No. 4,180,0~0 to Murphy granted December 25, 1979, a spiral coil, normally recessed within a guide tube, can be rotated whereby it emerges beyond the tube. U. S. Patent No. 3,844,292 to Bolduc granted October 29, 1974 discloses a plunger outside of the body which, after release of two locking mechanisms, is movable to push outward a barb-like tip. A somewhat similar arrangement, involving a platinum piston movable to push a harpoon-shaped anchor beyond the end of a tubular electrode, is shown in U. S. Patent No. 4,258,724 to Balat et al granted March 31, 1981.
Such devices, while satisfactory in certain respects, are undesirable in that leads employing them must have a larger diameter. They often require additional tools, for example a stylet-type screw driver for rotating the helix. Further, such devices are often over~y complex, diminishing their reliability and raising the possibility of a current leakage path between conductors of bipolar leads.
~herefore, it is an object of the present invention to provide a smooth, rounded covering for the anchoring element of a cardiac endocardial electrode to ~acilitate intravenous insertion of the electrode.
Another object of the invention i5 to provide such a covering which is soluble in body fluids, thereby to expose the ~32~700 anchoring element at a specified time after its initial insertion into the body.
Yet another object is to provide a simple, non-mechanical means for covering fixation mechanisms during intravenous insertion of a pacing electrode having an anchoring element, without requiring any longitudinal relative movement between the electrode and anchoring element.
SUMMARY OF THE INVENTION
To achieve these and other objects, there is provided an intravascular lead implantable inside a patient's body. The lead includes an electrode having a fixation element for effecting penetration into endocardial tissue at a selected location to secure the electrode at the selected location. The lead includes one or more flexible electrical conductors, and one or more flexible, biocompatible dielectric sheaths surrounding the conductors along substantially their entire length. A coupling means electrically and mechanically joins the electrode to a distal end of the conductor, whereby the conductor and electrode transmit electrical signals from the selected location to the lead proximal end. A biocompatible covering surrounds the fixation element and facilitates intravascular movement of the electrode. The covering is soluble in bodily fluids and has a thickness selected to allow at least a predetermined minimum time for the intravascular insertion of the lead and electrode, and 25 for the positioning of the electrode at least proximate to the , ~
selected location, before the covering dissolves sufficiently to ` expose the fixation element and permit the penetration~
~annitol, and other sugar derivatives, have been found suitable for forming the covering, which can be produced by dipping the fixation element into a beaker containing the D
~' 11 32~70~
mannitol or other covering constituent at a temperature slightly above its melting point. The fixation element i~ removed, cooling the element, along with a portion of material adhering to it. Alternatively, the covering can be preformed as a capsule, with a bore formed in the capsule for accommodating the fixation element. An adhesive is then used to join the covering to the electrode, with the fixation element inside the bore.
Another aspect of the present invention is an apparatus for facilitating intravascular insertion o~ a cardiac pacing electrode. The apparatus includes a biocompatible, non-pyrogenic covering substantially surrounding a fixation element of all electrode. The covering is soluble in hodily fluids and has a thickness selected to allow at lea~t a predetermined time for intravascular insertion of the electrode at least proximate a selected location inside the body of the patient, before the covering dissolves sufficiently to expose the fixation element to permit penetration of the fixation element into body tissue at the selected location.
As another aspect of the invention, there is disclosed a process for ~oating a fixation element o~ a body implantable electrode, including the steps of:
(a) selecting a biocompatible, non pyrogenic material soluble in bodily fluids and having a melting point substantially above normal body temperature, and heating the material to a temperature slightly above its melting point;
(b) dipping a fixation element of a body implantable eleckrode into a solution of the material maintained at said temperature;
(c) removing the fixation element, alon~ with an initial portion of the material adhering to the fixation element, ~ 3 ~
from the solution and permitting them to cool a sufficient time for said initial portion to at least partially solidify;
(d) dipping said fixation element and initial portion into the solution for a time suf~icient to permit a subsequent portion of the material to adhere to the initial portion; and (e) removing the fixation element, initial portion and ~ubsequent portion from the sclution, and permitting them to cool to an ambient temperature.
Steps (d) and (e) may be repeated until the thickness of the covering i5 sufficient for the desired dissolving time.
A covariny in accordance with the present invention, whether preformed or applied through dip coating, ~orms a smooth, blunt distal tip for its associated lead, allowing an expeditious, intravenous insertion of the lead, without concern that the fixation element will snag upon, tear or otherwise damage the vein or any other tissue as it travels toward the heart. A short time after the electrode reaches the selected cardiac chamber, there is a sufficient dissolving of the covering such that the fixation element is exposed and ready to penetrate the endocardium.
Due to the many materials suitable for the covering, which include various salts and polyvinylpyrrolidone as well as the aforementioned sugar derivatives, and further due to ~5 controlling the covsring thickness, a wide range of dissolving times is available, so that a particular covering can be tailored to the expected time for a particular procedure. Further refinement is provided by the preformed capsule, due to enhanced control over size, thickness and surface area of the covering.
o IN THE DRAWINGS
For a better appreciation of these and other features and advantages, reference is made to the following detailed description and the drawings, in which:
Figure 1 is a side sectional view of the distal end region of an implantable, positive fixation, cardiac lead;
Figure 2 is an enlarged side view showing the lead of Figure 1 provided with a soluble covering in accordance with the present invention;
Figure 3 is a view similar to that of Figure 2, illustrating the covering at an intermediate stage of its formation;
Figure 4 is a side view of a lead provided with a second embodiment covering;
Figure 5 is a side elevation of a lead provided with a third embodiment covering comprising a molded tip;
Figures 6 and 7 are side views of leads provided with coverings comprising pre-molded tips: and Figures 8 and 9 are top and side views, respectively, of a tool used in forming soluble coverings pursuant to the present invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
Turning now to the drawings, there is shown in Figure l the distal end region o~ an implantable, positive fixation, cardiac lead 16. Devices such as lead 16 typically are inserted intravenously, for example into the subclavian vein or the cephalic vein, and progressively moved toward the heart until the distal end reaches a selected cardiac chamber. With the distal tip positioned at a selected locationr the lead proximal end, still outside of the body, is maneuvered to implant the distal ~321~70~
tip into the endocardiu~. The implanted lead transmits electrical signals between the selected location in the heart and the lead proximal end, for one or both of two purposes: to monitor heart electrical activity at the selected location, and to carxy stimulating signals to the selected location from a pulse generator (not shown) connected to the lead proximal end.
To transmit the electrical signals therè is provided an electrical conductor, shown in Fi~ure 1 as a double-wound coil 18 formed of a nickel alloy. The coil provides maximum flexibility for conforming to the vein, with minimal stress on the conductor.
At the distal end of the lead is an electrode 20~ electrically and mechanically coupled to coil 18 by a platinum alloy crimp tube 22. A fl~xible, dielectric sheath 24 surrounds the coil and crimp tube. A suitable material for the sheath is silicone rubber.
Electrode 20 is porous, having a screen 26 formed of a platinum alloy. Screen 26 aids in chronic fixation, whereby fibrous connective tissue intertwines with the screen to firmly secure electrode 20. Fibrous encapsulation, however, can take weeks, and it is essential to provide a means for positively securing the lead distal end during the time immediately following implantation. To this end, there is provided a fixation helix 28 o~` platinum alloy. Helix 28 has a ~harp point at its distal end, which readily penetrates the endocardium.
Upon initial penetration, the helix is manipulated from the proximal end of lead 16, whereby it rotates clockwise, to further penetrate the tissue, to the point of firmly securing electrode 20 at the designated endocardial location.
A problem associated with helix 28 is that it~ sharp tip is capable of snagging and becoming entangled with the blood ~l326~00 vessel wall, venous valves, or heart valvs. Consequently, the physician using lead 16 typically is àdvised to rotate the helix counterclockwise, which tends to draw the sharp point of the helix away from the tissue it encounters, to minimize the potential for entanglement. Alternatively, protective devices, such as those discussed above, have been employed.
Fiyure 2 illustrates lead 16 with a covering or tip 30 mounted at its distal end in accordance with the present invention. Tip 30 is solid, and adheres to helix 28, screen 26 and the distal end of sheath 24. The outer surface o~ tip 30 is generally spheroid. However, the precise surface configuration is not so important as the fact that tip 30 i5 smooth, rounded and blunt, and that it completely surrounds fixation helix 28 to protect intravascular and other tissue from the ~ixation helix, particularly its sharp point 32.
Tip 30 is composed of a non-toxic, biocompatible and non-pyrogenic material. Also, the material must be soluble in body ~luids (particularly blood), within a temperature range encompassing normal body temperature (37 C.). Further, the material o~ tip 30 must maintain its structural integrity in an environment of body fluids at or about normal body temparature, in that it should not undergo plastic or elastic deformation as it dissolves. Usually the structural integrity re~uirement is satisfied if the melting point o~ the tip is substantially above normal body temperatures, in fact preferably 60 C. or higher.
In one example, tip 30 has been formed o~ mannitol, chemical formula C6H1406. Mannitol has a melting point of about 167 C., and one gram dissolves in about 5.5 milliliters of water, with solubility being greater in hot water. Mannitol in a glass beaker was first heated to a temperature between 177a and .
~8--` 132~7~
182 C., slightly above its melting point, and maintained at that temperature. The distal end of lead 16 was immersed in the mannitol solution for a brief time and withdrawn. A portion of the mannitol adhered to helix 28, forming a core portion 34 as illustrated in Figure 3. Away from the beaker, helix 28 and core portion 34 were allowed to cool a sufficient time for the core portion to solidify. This cooling required about five seconds.
Following cooling, the lead distal end was dipped into the mannitol melt once again, then withdrawn after about one second. A second portion of the mannitol melt, adhering to core portion 34, helix 28 and screen 26, was sufficient in combination with the core portion to form tip 30 as illustrated in Figure 2.
The spheroid tip configuration results from the natural surface tension nf the mannitol melt as it solidifies. A tip formed in this manner dissolves in water heated to about 38 C. in about three and one-half minutes.
Repeated trials of this example have yielded consistently satisfactory lead tips. The results indicate that the precise temperature of the mannitol melt is not critical, so long as it is maintained in liquid form, slightly above the melting point.
Likewise, the duration of each dip coating is not critical, although it must be sufficient for adherence o~ subsequent mannitol layers while not so long as to melt mannitol previously solidified onto the lead. Finally, as the number o~ dip coatings required is largely a function o~ d~sired tip size, certain tip designs may require substantially more than the two dip coatings described.
The dissolving time for tip 30 in body fluid is controlled principally by the tip material, surface area and thickness so that increased dissolving times can be provided, if - ~32~0 desired, by increasing the tip thickness. The main concern is that tip 30 be of sufficient slze to ènsure that lead 16 can be directed intravenously to the selected cardiac chamber prior to exposure of helix 28, particularly at point 32. Also of concern is that within a reasonably short time after insertion, tip 30 is completely dissolved to expose helix 28 for the implanting of electrode 20.
While the above example involves mannitol, other sugar derivatives stable at temperatures below 60 C. are suitable substitutesl for example dextrose, sorbose, sucrose, and glucosamine. Also usable are certain salts, for example sodium chloride, potassium chloride and sodium carbonate. A further suitable constituent is polyvinylpyrrolidone (PVP). These materials are suitable, as well, with non-helical fixation elements.
The dip process described above, when used to form tip 30, tends to trap air which expands due to heating, and can cause undesirable formation of bubbles in the tip. In such cases, it is advantaqeous to control the degree to which the lead distal end is submerged into the constituent melt. For example, Figure 4 illustrates a lead 36 in which a tip 40 entirely surrounds a fixation helix 42. ~ip 40 does not abut a sheath 44, but leaves a proximal portion 46 of a screen 4~ exposed. As a result of such controlled submerslon, air can escape through proximal portion 46, and later the proximal portion facilitates ethylene oxide sterilization of the lead distal end.
For improved control over the size and shape of the soluble tip, a tip 50 for a lead 52 is formed by a casting or injection molding of a constituent melt. The tip surrounds a helix 54 and screen 56, ko abut a sheath 58. As indicated at 60, --10~
- ~32~7~0 the profile of the tip along its side is linear, while a rounded blunt distal end 62 is retained. This allows a reduction of tip diameter to the nominal lead diameter, to further facilitate intravenous insertion.
Another method of controlling the size and shape of the tip is to preform the tip by casting or injection molding.
Figure 6 illustrates a lead 64 with a screen 65 and fixation helix 66 affixed to a conductor which i5 surrounded by a sheath 68. Surrounding the helix and screen is a preformed tip or capsule 70, fixed to sheath 68 using an adhesive at 72. Such adhesive can be the molten mat~rial itself in the case of mannitol, a heated syrup of fructose and sucrose which solidifies upon cooling, or syrups of other sugars (mannitol, sorbitol, etc.). A large diameter opening 74 is formed in capsule 70 to accommodate screen 65, while a cylindrical bore 76 o~ greater depth accommodates helix 66. As indicated by broken lines at 77 and 78, bore 76 can be shaped to provide a substantially uniform thickness in capsule 70 if desired. One or more openings, as indicated at 79, can be formed if desired to facilitate sterilization and increase the capsule surface area exposed to bodily fluids during lead insertion.
Although it requires an adhesive not needed in the dip coating or direct mold approach, a preformed tip has several significant ad~antages. First, it affords maximum control over the tip size and shape, so that a comparatively precise dissolving time can ~e achieved by appropriately selecting tip .
constituents and tip thickness. The resulting consistency among man~ tips renders the preformed tip the preferred choice for mass production. Also, the preformed tip requires less of the tip ~ 30 constituent. In particular, no constituent is provided where :
~ .
13267~
none is needed - namely, in the cylinder defined by the fixation helix. This factor contributes to more predictable dissolving times as well as material savings. Preformed tips are more amenable to being installed or replaced on site. Finally, constituents that cannot be melted because of their thermal instability, but which have the desired dissolving properties, can be formed into a tip such as tip 70 by compression or molding. Examples of such constituents are lactose, lecithin in combination with other materials, and glucosamine.
In Figure 7, an alternative preformed tip or capsule 80 is mounted to a lead 82 over its fixation helix 84 and screen 86.
A helical bore 88 is formed in tip 80, of a size and shape to accommodate helix 84, so that tip 80 is secured to lead 82 by turning it clockwise upon the helix. So mounted, tip 80 depends less upon an adhesive, and may not require any adhesive to connect it to a sheath 90.
Shown in Figures 8 and 9 is a forming tool 92, which is an aluminum block including two opposed sections 94 and g6 held together by socket head screws 98 and 100. The opposing walls of 20 sections 94 and 96 are cut away to form cavities 102, 104 and 106 when sections 94 and 96 are mounted with respect to each other as shown in the figures. Spacers, indicated at 108, maintain a slight gap between sections 94 and 96, preferably of about 0.005 inches.
The cavities are substantially identical in shape, although they can be formed in different sizes corresponding to tips of different selected sizes. Cavity 104, for example, includes a tip forming segment llO and an upper chamfered segment 112~ Tip forming segment llO has the desired cylindrical sides and rounded base to form the desired blunt tip, while chamfered ~ 13~7~
segment 112 facilitates insertion of tips prior to their shaping, and also serves as a temporary catch basin for excess melted tip material.
Forming tool 92 is used to control the size and shape of a soluble tip formed by the dip process described in connection with Figures 2 - 4. More particularly, the lead distal end is dipped in the mannitol solution, permitted to cool, then dipped again, this process being repeated a sufficient numher of times to form ~ tip larger than the desired size. Then, after heating forming tool 92 to a desired temperature, preferably slightly over the mannitol melting point, the tip formed by dip coating is momentarily inserted into the desired one of cavities 102 - 106, then quickly withdrawn, the desired time within the chosen cavity being a fraction of a second. During this brief insertion, the heated cavity wall melts the excess mannitol, whereupon the melt is removed by draining through the gap formed by spaces 108.
Part of the excess mannitol melt is collected briefly in chamfered segment 112 before drainage. While not necessary, the tip can be rotated slightly about a vertical axis while inserted, to further ensure the desired cylindrical sides and blunt end.
Whether formPd by dip coating, direct molding or molded separately for later attachment, a soluble tip in accordance with :the present invention renders cardiac pacing lead implantation safer and less traumatic to the patient. As it is moved toward ; 25 the heart through a selected vein, the tip dissolves, but at a sufficiently slow rate to prevent exposure of the fixation helix or other fixation element, until the electrode is at least near to its selected location along the endocardium. The smooth, rounded and blunt tip in fact expedites intravascular lead insertion. The tip thickness and constituent can be selected in ~32~7~0 accordance with the anticipated insertion time, with particular accuracy in the case of a preformed tip or capsule. Thus, within a brief period of time after proper positioning, the fixation helix or other fixation element can be manipulated from outside the body, in the usual manner, to secure the electrode.
What is claimed is:
.~
~O~UBLE COVERIN~ FO~ CA~DIAC PACIN~ ELECTRODE
BACKGROUND OF THE INVENTION
This invention relates to cardiac diagnostic and chronic therapeutic leads, and more particularly to fixation leads in which an electrode includes an anchoring element.
The utility of cardiac pacing leads is well recognized, both for carrying pulse stimulation signals ~o the heart from a pacemaker, and for monitoring heart electrical activity from outside the body. Many such leads are sufficiently flexible and small in diameter for intravenous introduction to a cardiac cavity, whereupon an electrode at the distal end of the lead is implanted into the endocardium to secure the lead. For this purpose, helical coils, barbs and other anchoring elements are provided, typically as part of the electrode.
The anchoring element must be sufficiently sharp to penetrate the endocardium and secure the e~ectrode against becoming detached, for example due to contractions of the myocardium. During a critical period immediately aftex implant and prior to full fibrotic growth, usually three to twelve weeks, the anchoring element must provide substantially the entire force maintaining the electrode in its selected location~ Given these requirements, it is not surprising that an effective anchoring alement can become entangled in the vein, heart valve or other tissue encountered during its intravenous insertion.
The problem has given rise to numerous proposed solutions. For example, U. S. Patent No. 3,974,834 to Kane granted August 17, 1976 shows a sleeve which shrouds the sharp tip of a fixation helix, but collapses in accordion-like fashion as the helix is turned into the endocardium. In U. S. Patent No.
30 4,282,885 to Bisping granted August 11, 1981, a protective core l~267~a is surrounded by the helix, and is movable axially relative to the helix. A wire, attached to the core, extends through the lead and can be pulled after lead insertion to withdraw the core, exposing the helix. U. S. Patent No. 4,146,036 to Dutcher et al granted March 27, 1975 discloses an extensible and retractable core surrounded by the helix.
Other solutions involve makiny the fixation element movable. For example, in U. S. Patent No. 4,180,0~0 to Murphy granted December 25, 1979, a spiral coil, normally recessed within a guide tube, can be rotated whereby it emerges beyond the tube. U. S. Patent No. 3,844,292 to Bolduc granted October 29, 1974 discloses a plunger outside of the body which, after release of two locking mechanisms, is movable to push outward a barb-like tip. A somewhat similar arrangement, involving a platinum piston movable to push a harpoon-shaped anchor beyond the end of a tubular electrode, is shown in U. S. Patent No. 4,258,724 to Balat et al granted March 31, 1981.
Such devices, while satisfactory in certain respects, are undesirable in that leads employing them must have a larger diameter. They often require additional tools, for example a stylet-type screw driver for rotating the helix. Further, such devices are often over~y complex, diminishing their reliability and raising the possibility of a current leakage path between conductors of bipolar leads.
~herefore, it is an object of the present invention to provide a smooth, rounded covering for the anchoring element of a cardiac endocardial electrode to ~acilitate intravenous insertion of the electrode.
Another object of the invention i5 to provide such a covering which is soluble in body fluids, thereby to expose the ~32~700 anchoring element at a specified time after its initial insertion into the body.
Yet another object is to provide a simple, non-mechanical means for covering fixation mechanisms during intravenous insertion of a pacing electrode having an anchoring element, without requiring any longitudinal relative movement between the electrode and anchoring element.
SUMMARY OF THE INVENTION
To achieve these and other objects, there is provided an intravascular lead implantable inside a patient's body. The lead includes an electrode having a fixation element for effecting penetration into endocardial tissue at a selected location to secure the electrode at the selected location. The lead includes one or more flexible electrical conductors, and one or more flexible, biocompatible dielectric sheaths surrounding the conductors along substantially their entire length. A coupling means electrically and mechanically joins the electrode to a distal end of the conductor, whereby the conductor and electrode transmit electrical signals from the selected location to the lead proximal end. A biocompatible covering surrounds the fixation element and facilitates intravascular movement of the electrode. The covering is soluble in bodily fluids and has a thickness selected to allow at least a predetermined minimum time for the intravascular insertion of the lead and electrode, and 25 for the positioning of the electrode at least proximate to the , ~
selected location, before the covering dissolves sufficiently to ` expose the fixation element and permit the penetration~
~annitol, and other sugar derivatives, have been found suitable for forming the covering, which can be produced by dipping the fixation element into a beaker containing the D
~' 11 32~70~
mannitol or other covering constituent at a temperature slightly above its melting point. The fixation element i~ removed, cooling the element, along with a portion of material adhering to it. Alternatively, the covering can be preformed as a capsule, with a bore formed in the capsule for accommodating the fixation element. An adhesive is then used to join the covering to the electrode, with the fixation element inside the bore.
Another aspect of the present invention is an apparatus for facilitating intravascular insertion o~ a cardiac pacing electrode. The apparatus includes a biocompatible, non-pyrogenic covering substantially surrounding a fixation element of all electrode. The covering is soluble in hodily fluids and has a thickness selected to allow at lea~t a predetermined time for intravascular insertion of the electrode at least proximate a selected location inside the body of the patient, before the covering dissolves sufficiently to expose the fixation element to permit penetration of the fixation element into body tissue at the selected location.
As another aspect of the invention, there is disclosed a process for ~oating a fixation element o~ a body implantable electrode, including the steps of:
(a) selecting a biocompatible, non pyrogenic material soluble in bodily fluids and having a melting point substantially above normal body temperature, and heating the material to a temperature slightly above its melting point;
(b) dipping a fixation element of a body implantable eleckrode into a solution of the material maintained at said temperature;
(c) removing the fixation element, alon~ with an initial portion of the material adhering to the fixation element, ~ 3 ~
from the solution and permitting them to cool a sufficient time for said initial portion to at least partially solidify;
(d) dipping said fixation element and initial portion into the solution for a time suf~icient to permit a subsequent portion of the material to adhere to the initial portion; and (e) removing the fixation element, initial portion and ~ubsequent portion from the sclution, and permitting them to cool to an ambient temperature.
Steps (d) and (e) may be repeated until the thickness of the covering i5 sufficient for the desired dissolving time.
A covariny in accordance with the present invention, whether preformed or applied through dip coating, ~orms a smooth, blunt distal tip for its associated lead, allowing an expeditious, intravenous insertion of the lead, without concern that the fixation element will snag upon, tear or otherwise damage the vein or any other tissue as it travels toward the heart. A short time after the electrode reaches the selected cardiac chamber, there is a sufficient dissolving of the covering such that the fixation element is exposed and ready to penetrate the endocardium.
Due to the many materials suitable for the covering, which include various salts and polyvinylpyrrolidone as well as the aforementioned sugar derivatives, and further due to ~5 controlling the covsring thickness, a wide range of dissolving times is available, so that a particular covering can be tailored to the expected time for a particular procedure. Further refinement is provided by the preformed capsule, due to enhanced control over size, thickness and surface area of the covering.
o IN THE DRAWINGS
For a better appreciation of these and other features and advantages, reference is made to the following detailed description and the drawings, in which:
Figure 1 is a side sectional view of the distal end region of an implantable, positive fixation, cardiac lead;
Figure 2 is an enlarged side view showing the lead of Figure 1 provided with a soluble covering in accordance with the present invention;
Figure 3 is a view similar to that of Figure 2, illustrating the covering at an intermediate stage of its formation;
Figure 4 is a side view of a lead provided with a second embodiment covering;
Figure 5 is a side elevation of a lead provided with a third embodiment covering comprising a molded tip;
Figures 6 and 7 are side views of leads provided with coverings comprising pre-molded tips: and Figures 8 and 9 are top and side views, respectively, of a tool used in forming soluble coverings pursuant to the present invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
Turning now to the drawings, there is shown in Figure l the distal end region o~ an implantable, positive fixation, cardiac lead 16. Devices such as lead 16 typically are inserted intravenously, for example into the subclavian vein or the cephalic vein, and progressively moved toward the heart until the distal end reaches a selected cardiac chamber. With the distal tip positioned at a selected locationr the lead proximal end, still outside of the body, is maneuvered to implant the distal ~321~70~
tip into the endocardiu~. The implanted lead transmits electrical signals between the selected location in the heart and the lead proximal end, for one or both of two purposes: to monitor heart electrical activity at the selected location, and to carxy stimulating signals to the selected location from a pulse generator (not shown) connected to the lead proximal end.
To transmit the electrical signals therè is provided an electrical conductor, shown in Fi~ure 1 as a double-wound coil 18 formed of a nickel alloy. The coil provides maximum flexibility for conforming to the vein, with minimal stress on the conductor.
At the distal end of the lead is an electrode 20~ electrically and mechanically coupled to coil 18 by a platinum alloy crimp tube 22. A fl~xible, dielectric sheath 24 surrounds the coil and crimp tube. A suitable material for the sheath is silicone rubber.
Electrode 20 is porous, having a screen 26 formed of a platinum alloy. Screen 26 aids in chronic fixation, whereby fibrous connective tissue intertwines with the screen to firmly secure electrode 20. Fibrous encapsulation, however, can take weeks, and it is essential to provide a means for positively securing the lead distal end during the time immediately following implantation. To this end, there is provided a fixation helix 28 o~` platinum alloy. Helix 28 has a ~harp point at its distal end, which readily penetrates the endocardium.
Upon initial penetration, the helix is manipulated from the proximal end of lead 16, whereby it rotates clockwise, to further penetrate the tissue, to the point of firmly securing electrode 20 at the designated endocardial location.
A problem associated with helix 28 is that it~ sharp tip is capable of snagging and becoming entangled with the blood ~l326~00 vessel wall, venous valves, or heart valvs. Consequently, the physician using lead 16 typically is àdvised to rotate the helix counterclockwise, which tends to draw the sharp point of the helix away from the tissue it encounters, to minimize the potential for entanglement. Alternatively, protective devices, such as those discussed above, have been employed.
Fiyure 2 illustrates lead 16 with a covering or tip 30 mounted at its distal end in accordance with the present invention. Tip 30 is solid, and adheres to helix 28, screen 26 and the distal end of sheath 24. The outer surface o~ tip 30 is generally spheroid. However, the precise surface configuration is not so important as the fact that tip 30 i5 smooth, rounded and blunt, and that it completely surrounds fixation helix 28 to protect intravascular and other tissue from the ~ixation helix, particularly its sharp point 32.
Tip 30 is composed of a non-toxic, biocompatible and non-pyrogenic material. Also, the material must be soluble in body ~luids (particularly blood), within a temperature range encompassing normal body temperature (37 C.). Further, the material o~ tip 30 must maintain its structural integrity in an environment of body fluids at or about normal body temparature, in that it should not undergo plastic or elastic deformation as it dissolves. Usually the structural integrity re~uirement is satisfied if the melting point o~ the tip is substantially above normal body temperatures, in fact preferably 60 C. or higher.
In one example, tip 30 has been formed o~ mannitol, chemical formula C6H1406. Mannitol has a melting point of about 167 C., and one gram dissolves in about 5.5 milliliters of water, with solubility being greater in hot water. Mannitol in a glass beaker was first heated to a temperature between 177a and .
~8--` 132~7~
182 C., slightly above its melting point, and maintained at that temperature. The distal end of lead 16 was immersed in the mannitol solution for a brief time and withdrawn. A portion of the mannitol adhered to helix 28, forming a core portion 34 as illustrated in Figure 3. Away from the beaker, helix 28 and core portion 34 were allowed to cool a sufficient time for the core portion to solidify. This cooling required about five seconds.
Following cooling, the lead distal end was dipped into the mannitol melt once again, then withdrawn after about one second. A second portion of the mannitol melt, adhering to core portion 34, helix 28 and screen 26, was sufficient in combination with the core portion to form tip 30 as illustrated in Figure 2.
The spheroid tip configuration results from the natural surface tension nf the mannitol melt as it solidifies. A tip formed in this manner dissolves in water heated to about 38 C. in about three and one-half minutes.
Repeated trials of this example have yielded consistently satisfactory lead tips. The results indicate that the precise temperature of the mannitol melt is not critical, so long as it is maintained in liquid form, slightly above the melting point.
Likewise, the duration of each dip coating is not critical, although it must be sufficient for adherence o~ subsequent mannitol layers while not so long as to melt mannitol previously solidified onto the lead. Finally, as the number o~ dip coatings required is largely a function o~ d~sired tip size, certain tip designs may require substantially more than the two dip coatings described.
The dissolving time for tip 30 in body fluid is controlled principally by the tip material, surface area and thickness so that increased dissolving times can be provided, if - ~32~0 desired, by increasing the tip thickness. The main concern is that tip 30 be of sufficient slze to ènsure that lead 16 can be directed intravenously to the selected cardiac chamber prior to exposure of helix 28, particularly at point 32. Also of concern is that within a reasonably short time after insertion, tip 30 is completely dissolved to expose helix 28 for the implanting of electrode 20.
While the above example involves mannitol, other sugar derivatives stable at temperatures below 60 C. are suitable substitutesl for example dextrose, sorbose, sucrose, and glucosamine. Also usable are certain salts, for example sodium chloride, potassium chloride and sodium carbonate. A further suitable constituent is polyvinylpyrrolidone (PVP). These materials are suitable, as well, with non-helical fixation elements.
The dip process described above, when used to form tip 30, tends to trap air which expands due to heating, and can cause undesirable formation of bubbles in the tip. In such cases, it is advantaqeous to control the degree to which the lead distal end is submerged into the constituent melt. For example, Figure 4 illustrates a lead 36 in which a tip 40 entirely surrounds a fixation helix 42. ~ip 40 does not abut a sheath 44, but leaves a proximal portion 46 of a screen 4~ exposed. As a result of such controlled submerslon, air can escape through proximal portion 46, and later the proximal portion facilitates ethylene oxide sterilization of the lead distal end.
For improved control over the size and shape of the soluble tip, a tip 50 for a lead 52 is formed by a casting or injection molding of a constituent melt. The tip surrounds a helix 54 and screen 56, ko abut a sheath 58. As indicated at 60, --10~
- ~32~7~0 the profile of the tip along its side is linear, while a rounded blunt distal end 62 is retained. This allows a reduction of tip diameter to the nominal lead diameter, to further facilitate intravenous insertion.
Another method of controlling the size and shape of the tip is to preform the tip by casting or injection molding.
Figure 6 illustrates a lead 64 with a screen 65 and fixation helix 66 affixed to a conductor which i5 surrounded by a sheath 68. Surrounding the helix and screen is a preformed tip or capsule 70, fixed to sheath 68 using an adhesive at 72. Such adhesive can be the molten mat~rial itself in the case of mannitol, a heated syrup of fructose and sucrose which solidifies upon cooling, or syrups of other sugars (mannitol, sorbitol, etc.). A large diameter opening 74 is formed in capsule 70 to accommodate screen 65, while a cylindrical bore 76 o~ greater depth accommodates helix 66. As indicated by broken lines at 77 and 78, bore 76 can be shaped to provide a substantially uniform thickness in capsule 70 if desired. One or more openings, as indicated at 79, can be formed if desired to facilitate sterilization and increase the capsule surface area exposed to bodily fluids during lead insertion.
Although it requires an adhesive not needed in the dip coating or direct mold approach, a preformed tip has several significant ad~antages. First, it affords maximum control over the tip size and shape, so that a comparatively precise dissolving time can ~e achieved by appropriately selecting tip .
constituents and tip thickness. The resulting consistency among man~ tips renders the preformed tip the preferred choice for mass production. Also, the preformed tip requires less of the tip ~ 30 constituent. In particular, no constituent is provided where :
~ .
13267~
none is needed - namely, in the cylinder defined by the fixation helix. This factor contributes to more predictable dissolving times as well as material savings. Preformed tips are more amenable to being installed or replaced on site. Finally, constituents that cannot be melted because of their thermal instability, but which have the desired dissolving properties, can be formed into a tip such as tip 70 by compression or molding. Examples of such constituents are lactose, lecithin in combination with other materials, and glucosamine.
In Figure 7, an alternative preformed tip or capsule 80 is mounted to a lead 82 over its fixation helix 84 and screen 86.
A helical bore 88 is formed in tip 80, of a size and shape to accommodate helix 84, so that tip 80 is secured to lead 82 by turning it clockwise upon the helix. So mounted, tip 80 depends less upon an adhesive, and may not require any adhesive to connect it to a sheath 90.
Shown in Figures 8 and 9 is a forming tool 92, which is an aluminum block including two opposed sections 94 and g6 held together by socket head screws 98 and 100. The opposing walls of 20 sections 94 and 96 are cut away to form cavities 102, 104 and 106 when sections 94 and 96 are mounted with respect to each other as shown in the figures. Spacers, indicated at 108, maintain a slight gap between sections 94 and 96, preferably of about 0.005 inches.
The cavities are substantially identical in shape, although they can be formed in different sizes corresponding to tips of different selected sizes. Cavity 104, for example, includes a tip forming segment llO and an upper chamfered segment 112~ Tip forming segment llO has the desired cylindrical sides and rounded base to form the desired blunt tip, while chamfered ~ 13~7~
segment 112 facilitates insertion of tips prior to their shaping, and also serves as a temporary catch basin for excess melted tip material.
Forming tool 92 is used to control the size and shape of a soluble tip formed by the dip process described in connection with Figures 2 - 4. More particularly, the lead distal end is dipped in the mannitol solution, permitted to cool, then dipped again, this process being repeated a sufficient numher of times to form ~ tip larger than the desired size. Then, after heating forming tool 92 to a desired temperature, preferably slightly over the mannitol melting point, the tip formed by dip coating is momentarily inserted into the desired one of cavities 102 - 106, then quickly withdrawn, the desired time within the chosen cavity being a fraction of a second. During this brief insertion, the heated cavity wall melts the excess mannitol, whereupon the melt is removed by draining through the gap formed by spaces 108.
Part of the excess mannitol melt is collected briefly in chamfered segment 112 before drainage. While not necessary, the tip can be rotated slightly about a vertical axis while inserted, to further ensure the desired cylindrical sides and blunt end.
Whether formPd by dip coating, direct molding or molded separately for later attachment, a soluble tip in accordance with :the present invention renders cardiac pacing lead implantation safer and less traumatic to the patient. As it is moved toward ; 25 the heart through a selected vein, the tip dissolves, but at a sufficiently slow rate to prevent exposure of the fixation helix or other fixation element, until the electrode is at least near to its selected location along the endocardium. The smooth, rounded and blunt tip in fact expedites intravascular lead insertion. The tip thickness and constituent can be selected in ~32~7~0 accordance with the anticipated insertion time, with particular accuracy in the case of a preformed tip or capsule. Thus, within a brief period of time after proper positioning, the fixation helix or other fixation element can be manipulated from outside the body, in the usual manner, to secure the electrode.
What is claimed is:
.~
Claims (21)
1. An intravascular lead implantable inside a patient, including:
an electrode having a fixation element for effecting penetration into endocardial tissue at a selected location to secure said electrode at said selected location; a flexible electrical conductor; a flexible, biocompatible dielectric sheath surrounding said conductor along substantially the entire length thereof; and a coupling means for electrically and mechanically joining said electrode to a distal end of said conductor, whereby the conductor and electrode transmit electrical signals between said selected location and a proximal end of said conductor; and a biocompatible covering surrounding said fixation element for facilitating intravascular movement of said electrode, said covering soluble in body fluids, stable in an ambient environment, having a melting point of at least 60° C., tending to maintain its structural integrity in an environment of bodily fluids at approximately body temperature, and having a thickness selected to allow at least a predetermined minimum time for the intravascular insertion of said lead and electrode and the positioning of said electrode at least proximate said selected location, before said covering dissolves sufficiently to expose said fixation element and permit said penetration, said covering consisting essentially of at least one of the following constituents: mannitol; dextrose; sorbose; sucrose; sodium chloride; potassium chloride; and sodium carbonate.
an electrode having a fixation element for effecting penetration into endocardial tissue at a selected location to secure said electrode at said selected location; a flexible electrical conductor; a flexible, biocompatible dielectric sheath surrounding said conductor along substantially the entire length thereof; and a coupling means for electrically and mechanically joining said electrode to a distal end of said conductor, whereby the conductor and electrode transmit electrical signals between said selected location and a proximal end of said conductor; and a biocompatible covering surrounding said fixation element for facilitating intravascular movement of said electrode, said covering soluble in body fluids, stable in an ambient environment, having a melting point of at least 60° C., tending to maintain its structural integrity in an environment of bodily fluids at approximately body temperature, and having a thickness selected to allow at least a predetermined minimum time for the intravascular insertion of said lead and electrode and the positioning of said electrode at least proximate said selected location, before said covering dissolves sufficiently to expose said fixation element and permit said penetration, said covering consisting essentially of at least one of the following constituents: mannitol; dextrose; sorbose; sucrose; sodium chloride; potassium chloride; and sodium carbonate.
2. The intravascular lead of Claim 1 wherein:
said covering consists essentially of mannitol.
said covering consists essentially of mannitol.
3. The intravascular lead of Claim 1 wherein:
said covering consists of one of said constituents.
said covering consists of one of said constituents.
4. The intravascular lead of Claim 1 wherein:
said covering comprises a preformed capsule with means forming a bore in said capsule for accommodating said fixation element, and means joining said capsule with respect to said electrode with said fixation element inside of said bore.
said covering comprises a preformed capsule with means forming a bore in said capsule for accommodating said fixation element, and means joining said capsule with respect to said electrode with said fixation element inside of said bore.
5. The intravascular lead of Claim 4 wherein:
said joining means comprises an adhesive.
said joining means comprises an adhesive.
6. The intravascular lead of Claim 4 wherein:
said fixation element is a helix, and said bore has a helical shape corresponding to the shape of said helix.
said fixation element is a helix, and said bore has a helical shape corresponding to the shape of said helix.
7. The intravascular lead of Claim 1 wherein:
said electrode includes an electrically conductive and porous electrode portion proximally of said fixation element.
said electrode includes an electrically conductive and porous electrode portion proximally of said fixation element.
8. The intravascular lead of Claim 7 wherein:
said covering overlies part of said porous electrode portion and leaves the remainder of said portion exposed.
said covering overlies part of said porous electrode portion and leaves the remainder of said portion exposed.
9. An apparatus for facilitating intravascular insertion of a body implantable device, comprising:
a body implantable device, a fixation element at a distal end of said device, and a biocompatible, non-pyroganic covering substantially surrounding said fixation element, said covering having a melting point of at least 60° C., being stable in an ambient environment, soluble in body fluids, tending to maintain its structural integrity in an environment of bodily fluids at approximately body temperature, and having a thickness selected to allow at least a predetermined time for the intravascular insertion of said distal end at least proximate to a selected location inside a body of a living animal, before said covering dissolves sufficiently to expose said fixation element to permit penetration of the fixation element into body tissue at said selected location, said covering consisting essentially of at least one of the following constituents: mannitol; dextrose;
sorbose; sucrose; sodium chloride; sodium carbonate; and potassium chloride.
a body implantable device, a fixation element at a distal end of said device, and a biocompatible, non-pyroganic covering substantially surrounding said fixation element, said covering having a melting point of at least 60° C., being stable in an ambient environment, soluble in body fluids, tending to maintain its structural integrity in an environment of bodily fluids at approximately body temperature, and having a thickness selected to allow at least a predetermined time for the intravascular insertion of said distal end at least proximate to a selected location inside a body of a living animal, before said covering dissolves sufficiently to expose said fixation element to permit penetration of the fixation element into body tissue at said selected location, said covering consisting essentially of at least one of the following constituents: mannitol; dextrose;
sorbose; sucrose; sodium chloride; sodium carbonate; and potassium chloride.
10. The apparatus of Claim 9 wherein:
said covering consists essentially of mannitol.
said covering consists essentially of mannitol.
11. The apparatus of Claim 9 wherein:
said covering consists essentially of one of said constituents.
said covering consists essentially of one of said constituents.
12. The apparatus of Claim 9 wherein:
said body implantable device comprises a cardiac pacing electrode.
said body implantable device comprises a cardiac pacing electrode.
13. The apparatus of Claim 12 wherein:
said covering is formed by dip coating a material comprising said covering in liquid melt form onto said fixation element for solidifying in surrounding relation to said element.
said covering is formed by dip coating a material comprising said covering in liquid melt form onto said fixation element for solidifying in surrounding relation to said element.
14. The apparatus of Claim 12 wherein:
said covering comprises a preformed capsule and means forming a bore in said capsule to accommodate said fixation element, said apparatus further including means for connecting said capsule with respect to said electrode with said fixation element contained in said bore.
said covering comprises a preformed capsule and means forming a bore in said capsule to accommodate said fixation element, said apparatus further including means for connecting said capsule with respect to said electrode with said fixation element contained in said bore.
15. The apparatus of Claim 14 wherein:
said fixation element is a helix, and said bore has a helical shape corresponding to the shape of said helix.
said fixation element is a helix, and said bore has a helical shape corresponding to the shape of said helix.
16. The apparatus of Claim 14 wherein:
said electrode includes a porous screen, and said capsule, when connected with respect to said electrode, overlies most of said screen, leaving the remainder of said screen exposed.
said electrode includes a porous screen, and said capsule, when connected with respect to said electrode, overlies most of said screen, leaving the remainder of said screen exposed.
17. The apparatus of Claim 12 wherein:
said electrode includes an electrically conductive and porous screen located proximally of said fixation element, and said electrode is selectively dip coated to cover said fixation element and a portion of said screen, leaving the remainder of said screen exposed.
said electrode includes an electrically conductive and porous screen located proximally of said fixation element, and said electrode is selectively dip coated to cover said fixation element and a portion of said screen, leaving the remainder of said screen exposed.
18. A process for coating a fixation element of a body implantable electrode, including the steps of:
(a) selecting a biocompatible, non-pyrogenic material soluble in bodily fluids and having a melting point substantially above normal body temperature, and heating said material to a temperature slightly above its melting point;
(b) dipping a fixation element of a body implantable electrode into a solution of said material maintained at said temperature;
(c) removing said fixation member, along with an initial portion of said material adhering to said fixation member, from said solution and permitting them to cool a sufficient time to allow said first portion to at least partially solidify;
(d) dipping said fixation member and material portion, after said cooling, into said solution for a time sufficient to permit a subsequent portion of said material to adhere to said initial portion; and (e) removing said fixation member, initial portion and subsequent portion from said solution, and permitting them to cool to an ambient temperature.
(a) selecting a biocompatible, non-pyrogenic material soluble in bodily fluids and having a melting point substantially above normal body temperature, and heating said material to a temperature slightly above its melting point;
(b) dipping a fixation element of a body implantable electrode into a solution of said material maintained at said temperature;
(c) removing said fixation member, along with an initial portion of said material adhering to said fixation member, from said solution and permitting them to cool a sufficient time to allow said first portion to at least partially solidify;
(d) dipping said fixation member and material portion, after said cooling, into said solution for a time sufficient to permit a subsequent portion of said material to adhere to said initial portion; and (e) removing said fixation member, initial portion and subsequent portion from said solution, and permitting them to cool to an ambient temperature.
19. The process of Claim 18 including the further steps of:
repeating steps (d) and (e) until the combined thickness of said initial portion and all subsequent portions is at least a predetermined value.
repeating steps (d) and (e) until the combined thickness of said initial portion and all subsequent portions is at least a predetermined value.
20. The process of Claim 18 including the further steps of:
providing means defining a cavity having a selected size and shape, and heating a wall forming said cavity to a preselected temperature at least as high as the melting point of said material; and with the combined thickness of said material portions being at least said predetermined value to form a tip larger than said cavity, momentarily inserting said tip into said cavity to melt excess material; and draining said excess material from said cavity.
providing means defining a cavity having a selected size and shape, and heating a wall forming said cavity to a preselected temperature at least as high as the melting point of said material; and with the combined thickness of said material portions being at least said predetermined value to form a tip larger than said cavity, momentarily inserting said tip into said cavity to melt excess material; and draining said excess material from said cavity.
21. An intravascular lead implantable inside a patient, including:
an electrode having a fixation element for effecting penetration into endocardial tissue at a selected location to secure said electrode at said selected location; a flexible electrical conductor; a flexible, biocompatible dielectric sheath surrounding said conductor along substantially the entire length thereof; and a coupling means for electrically and mechanically joining said electrode to a distal end of said conductor, whereby the conductor and electrode transmit electrical signals between said selected location and a proximal end of said conductor; and a biocompatible covering surrouding said fixation element for facilitating intravascular movement of said electrode, said covering soluble in body fluids, stable in an ambient environment, having a melting point of at least 60° C., tending to maintain its structural integrity in an environment of bodily fluids at approximatley body temperature, and having a thickness selected to allow at least a predetermined minimum time for the intravascular insertion of said electrode and the positioning of said electrode at least proximate said selected location, before said covering dissolves sufficiently to expose said fixation element and permit said penetration, wherein said covering is formed by dip coating said fixation element with a liquid melt of material comprising said covering.
an electrode having a fixation element for effecting penetration into endocardial tissue at a selected location to secure said electrode at said selected location; a flexible electrical conductor; a flexible, biocompatible dielectric sheath surrounding said conductor along substantially the entire length thereof; and a coupling means for electrically and mechanically joining said electrode to a distal end of said conductor, whereby the conductor and electrode transmit electrical signals between said selected location and a proximal end of said conductor; and a biocompatible covering surrouding said fixation element for facilitating intravascular movement of said electrode, said covering soluble in body fluids, stable in an ambient environment, having a melting point of at least 60° C., tending to maintain its structural integrity in an environment of bodily fluids at approximatley body temperature, and having a thickness selected to allow at least a predetermined minimum time for the intravascular insertion of said electrode and the positioning of said electrode at least proximate said selected location, before said covering dissolves sufficiently to expose said fixation element and permit said penetration, wherein said covering is formed by dip coating said fixation element with a liquid melt of material comprising said covering.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/037,684 US4827940A (en) | 1987-04-13 | 1987-04-13 | Soluble covering for cardiac pacing electrode |
| US07/272,912 US4876109A (en) | 1987-04-13 | 1988-11-18 | Soluble covering for cardiac pacing electrode |
| CA000585746A CA1326700C (en) | 1987-04-13 | 1988-12-13 | Soluble covering for cardiac pacing electrode |
| EP88311860A EP0337035B1 (en) | 1987-04-13 | 1988-12-15 | Soluble covering for cardiac pacing electrode |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/037,684 US4827940A (en) | 1987-04-13 | 1987-04-13 | Soluble covering for cardiac pacing electrode |
| CA000585746A CA1326700C (en) | 1987-04-13 | 1988-12-13 | Soluble covering for cardiac pacing electrode |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1326700C true CA1326700C (en) | 1994-02-01 |
Family
ID=25672298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000585746A Expired - Fee Related CA1326700C (en) | 1987-04-13 | 1988-12-13 | Soluble covering for cardiac pacing electrode |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US4827940A (en) |
| EP (1) | EP0337035B1 (en) |
| CA (1) | CA1326700C (en) |
Families Citing this family (136)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5254105A (en) * | 1988-05-26 | 1993-10-19 | Haaga John R | Sheath for wound closure caused by a medical tubular device |
| US5195988A (en) * | 1988-05-26 | 1993-03-23 | Haaga John R | Medical needle with removable sheath |
| US5330445A (en) * | 1988-05-26 | 1994-07-19 | Haaga John R | Sheath for wound closure caused by a medical tubular device |
| US5080655A (en) * | 1988-05-26 | 1992-01-14 | Haaga John R | Medical biopsy needle |
| US4936835A (en) * | 1988-05-26 | 1990-06-26 | Haaga John R | Medical needle with bioabsorbable tip |
| US5049138A (en) * | 1989-11-13 | 1991-09-17 | Boston Scientific Corporation | Catheter with dissolvable tip |
| US5441739A (en) * | 1990-06-22 | 1995-08-15 | The Regents Of The University Of California | Reduced and controlled surface binding of biologically active molecules |
| ATE116563T1 (en) * | 1990-12-14 | 1995-01-15 | Osypka Peter | HEART PACEMAKER LEAD WITH SCREW COIL. |
| GB2267415B (en) * | 1992-05-19 | 1996-02-07 | Sony Broadcast & Communication | Signal switching |
| FR2693115B1 (en) * | 1992-07-02 | 1994-08-19 | Celsa Lg | Implantable electrical conductor and stimulation set, particularly for the heart. |
| US5447533A (en) * | 1992-09-03 | 1995-09-05 | Pacesetter, Inc. | Implantable stimulation lead having an advanceable therapeutic drug delivery system |
| US5324324A (en) * | 1992-10-13 | 1994-06-28 | Siemens Pacesetter, Inc. | Coated implantable stimulation electrode and lead |
| US5263977A (en) * | 1992-10-26 | 1993-11-23 | Angeion Corporation | Electrode spacing device |
| US5385579A (en) * | 1993-03-30 | 1995-01-31 | Siemens Pacesetter, Inc. | Myocardial body implantable lead |
| US5401257A (en) * | 1993-04-27 | 1995-03-28 | Boston Scientific Corporation | Ureteral stents, drainage tubes and the like |
| US5431639A (en) * | 1993-08-12 | 1995-07-11 | Boston Scientific Corporation | Treating wounds caused by medical procedures |
| USH1465H (en) * | 1993-09-08 | 1995-07-04 | Medtronic, Inc. | Implantable lead infection barrier |
| US5487392A (en) * | 1993-11-15 | 1996-01-30 | Haaga; John R. | Biopxy system with hemostatic insert |
| US5476500A (en) * | 1993-12-20 | 1995-12-19 | Ventritex, Inc. | Endocardial lead system with defibrillation electrode fixation |
| US5477862A (en) * | 1994-03-14 | 1995-12-26 | Haaga; John R. | Cutting tip for biopsy needle |
| US5522875A (en) | 1994-07-28 | 1996-06-04 | Medtronic, Inc. | Medical electrical lead system having a torque transfer stylet |
| US5522874A (en) * | 1994-07-28 | 1996-06-04 | Gates; James T. | Medical lead having segmented electrode |
| US5522876A (en) * | 1994-10-26 | 1996-06-04 | Vitatron Medical, B.V. | Screw-in pacing lead |
| US5545206A (en) * | 1994-12-22 | 1996-08-13 | Ventritex, Inc. | Low profile lead with automatic tine activation |
| US5531783A (en) * | 1995-01-17 | 1996-07-02 | Vitatron Medical, B.V. | Pacing lead with x-ray visible soluble covering and method of inserting same into a patient's heart |
| US5716391A (en) * | 1995-08-23 | 1998-02-10 | Medtronic, Inc. | Medical electrical lead having temporarily rigid fixation |
| SE9503144D0 (en) * | 1995-09-12 | 1995-09-12 | Pacesetter Ab | Protective body for implantable electrical conductor and electric conductor provided with such end protection |
| AU702746B2 (en) * | 1995-09-20 | 1999-03-04 | Cochlear Limited | Bioresorbable polymer use in cochlear and other implants |
| US5658327A (en) * | 1995-12-19 | 1997-08-19 | Ventritex, Inc. | Intracardiac lead having a compliant fixation device |
| US5683447A (en) * | 1995-12-19 | 1997-11-04 | Ventritex, Inc. | Lead with septal defibrillation and pacing electrodes |
| US5741321A (en) | 1996-01-11 | 1998-04-21 | Medtronic, Inc. | Active fixation medical electrical lead having improved turning tool |
| US5776178A (en) * | 1996-02-21 | 1998-07-07 | Medtronic, Inc. | Medical electrical lead with surface treatment for enhanced fixation |
| US5830217A (en) * | 1996-08-09 | 1998-11-03 | Thomas J. Fogarty | Soluble fixation device and method for stent delivery catheters |
| US6001094A (en) * | 1997-01-09 | 1999-12-14 | Vidacare International, Inc. | Implantable soluble electrode system |
| US6752812B1 (en) | 1997-05-15 | 2004-06-22 | Regent Of The University Of Minnesota | Remote actuation of trajectory guide |
| US5993463A (en) | 1997-05-15 | 1999-11-30 | Regents Of The University Of Minnesota | Remote actuation of trajectory guide |
| US6296615B1 (en) | 1999-03-05 | 2001-10-02 | Data Sciences International, Inc. | Catheter with physiological sensor |
| US6409674B1 (en) | 1998-09-24 | 2002-06-25 | Data Sciences International, Inc. | Implantable sensor with wireless communication |
| US6033366A (en) | 1997-10-14 | 2000-03-07 | Data Sciences International, Inc. | Pressure measurement device |
| US6141594A (en) * | 1998-07-22 | 2000-10-31 | Cardiac Pacemakers, Inc. | Single pass lead and system with active and passive fixation elements |
| US6097986A (en) * | 1997-12-17 | 2000-08-01 | Cardiac Pacemakers, Inc. | Retractable lead with mesh screen |
| US6501994B1 (en) * | 1997-12-24 | 2002-12-31 | Cardiac Pacemakers, Inc. | High impedance electrode tip |
| US5942276A (en) * | 1998-01-16 | 1999-08-24 | Medtronic, Inc. | Method of manufacturing x-ray visible soluble covering |
| US6091978A (en) | 1998-04-07 | 2000-07-18 | Cardiac Pacemakers, Inc. | Removable cap for tissue-insertable connections |
| US6501990B1 (en) | 1999-12-23 | 2002-12-31 | Cardiac Pacemakers, Inc. | Extendable and retractable lead having a snap-fit terminal connector |
| US6463334B1 (en) * | 1998-11-02 | 2002-10-08 | Cardiac Pacemakers, Inc. | Extendable and retractable lead |
| US6195577B1 (en) | 1998-10-08 | 2001-02-27 | Regents Of The University Of Minnesota | Method and apparatus for positioning a device in a body |
| US6190383B1 (en) | 1998-10-21 | 2001-02-20 | Sherwood Services Ag | Rotatable electrode device |
| US6473633B1 (en) * | 1999-07-29 | 2002-10-29 | Cardiac Pacemakers, Inc. | Removable cap for tissue-insertable connections |
| US6360129B1 (en) | 1999-12-13 | 2002-03-19 | Cardiac Pacemakers, Inc. | Mannitol/hydrogel cap for tissue-insertable connections |
| AU2002345328A1 (en) | 2001-06-27 | 2003-03-03 | Remon Medical Technologies Ltd. | Method and device for electrochemical formation of therapeutic species in vivo |
| US7363091B1 (en) * | 2001-07-11 | 2008-04-22 | Pacesetter Inc. | Method of molding silicone elastomer drug carrier in an endocardial lead |
| US6941174B2 (en) * | 2001-12-31 | 2005-09-06 | Ethicon, Inc. | Temporary pacing wire having a constrained anchor and method of producing same |
| US6855115B2 (en) | 2002-01-22 | 2005-02-15 | Cardiomems, Inc. | Implantable wireless sensor for pressure measurement within the heart |
| US7699059B2 (en) | 2002-01-22 | 2010-04-20 | Cardiomems, Inc. | Implantable wireless sensor |
| US8968178B2 (en) | 2002-03-07 | 2015-03-03 | Ams Research Corporation | Transobturator surgical articles and methods |
| US7147604B1 (en) | 2002-08-07 | 2006-12-12 | Cardiomems, Inc. | High Q factor sensor |
| DE10316177B4 (en) * | 2003-04-10 | 2007-05-31 | Cardiac Pacemakers, Inc., St. Paul | Pacemaker electrode arrangement |
| US20040230282A1 (en) * | 2003-04-11 | 2004-11-18 | Cates Adam W. | Acute and chronic fixation for subcutaneous electrodes |
| US7493175B2 (en) * | 2003-04-11 | 2009-02-17 | Cardiac Pacemakers, Inc. | Subcutaneous lead with tined fixation |
| US7499758B2 (en) | 2003-04-11 | 2009-03-03 | Cardiac Pacemakers, Inc. | Helical fixation elements for subcutaneous electrodes |
| US7245117B1 (en) | 2004-11-01 | 2007-07-17 | Cardiomems, Inc. | Communicating with implanted wireless sensor |
| US8026729B2 (en) | 2003-09-16 | 2011-09-27 | Cardiomems, Inc. | System and apparatus for in-vivo assessment of relative position of an implant |
| WO2005027998A2 (en) | 2003-09-16 | 2005-03-31 | Cardiomems, Inc. | Implantable wireless sensor |
| US7488343B2 (en) | 2003-09-16 | 2009-02-10 | Boston Scientific Scimed, Inc. | Medical devices |
| EP1682215B1 (en) * | 2003-10-24 | 2008-12-24 | Cardiac Pacemakers, Inc. | Myocardial lead attachment system |
| US7499759B2 (en) * | 2003-10-24 | 2009-03-03 | Cardiac Pacemakers, Inc. | Distal or proximal fixation of over-the-tether myocardial leads |
| WO2005046470A1 (en) * | 2003-11-06 | 2005-05-26 | The Regents Of The University Of Colorado, A Body Corporate | Shape-memory polymer coated electrodes |
| US7933661B2 (en) * | 2004-02-04 | 2011-04-26 | Medtronic, Inc. | Lead retention means |
| US7212869B2 (en) * | 2004-02-04 | 2007-05-01 | Medtronic, Inc. | Lead retention means |
| US8137397B2 (en) | 2004-02-26 | 2012-03-20 | Boston Scientific Scimed, Inc. | Medical devices |
| EP1768741B1 (en) | 2004-06-17 | 2014-12-31 | Medtronic, Inc. | Novel lead retention means |
| EP1618919B1 (en) | 2004-07-20 | 2012-07-04 | Biotronik CRM Patent AG | Fixation means for implantable electrodes and catheters |
| US7914437B2 (en) * | 2005-02-04 | 2011-03-29 | Ams Research Corporation | Transobturator methods for installing sling to treat incontinence, and related devices |
| CA2596277C (en) * | 2005-02-04 | 2012-07-10 | Ams Research Corporation | Needle design for male transobturator sling |
| US7662653B2 (en) | 2005-02-10 | 2010-02-16 | Cardiomems, Inc. | Method of manufacturing a hermetic chamber with electrical feedthroughs |
| US7647836B2 (en) | 2005-02-10 | 2010-01-19 | Cardiomems, Inc. | Hermetic chamber with electrical feedthroughs |
| US8021307B2 (en) | 2005-03-03 | 2011-09-20 | Cardiomems, Inc. | Apparatus and method for sensor deployment and fixation |
| US8118749B2 (en) | 2005-03-03 | 2012-02-21 | Cardiomems, Inc. | Apparatus and method for sensor deployment and fixation |
| US7763037B2 (en) * | 2005-03-18 | 2010-07-27 | Castlewood Surgical, Inc. | System and method for attaching a vein, an artery, or a tube in a vascular environment |
| US20060235499A1 (en) * | 2005-04-14 | 2006-10-19 | Cardiac Pacemakers, Inc. | Coated lead fixation electrode |
| US7477946B2 (en) * | 2005-04-26 | 2009-01-13 | Cardiac Pacemakers, Inc. | Fixation device for coronary venous lead |
| US8175724B2 (en) * | 2005-04-26 | 2012-05-08 | Cardiac Pacemakers, Inc. | Vascular fixation device |
| US20060247753A1 (en) * | 2005-04-29 | 2006-11-02 | Wenger William K | Subcutaneous lead fixation mechanisms |
| WO2007002185A2 (en) | 2005-06-21 | 2007-01-04 | Cardiomems, Inc. | Method of manufacturing implantable wireless sensor for in vivo pressure measurement |
| EP2471448A1 (en) | 2005-10-14 | 2012-07-04 | Nanostim, Inc. | Leadless cardiac pacemaker and system |
| US9168383B2 (en) | 2005-10-14 | 2015-10-27 | Pacesetter, Inc. | Leadless cardiac pacemaker with conducted communication |
| US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
| US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
| US8059625B2 (en) * | 2006-02-03 | 2011-11-15 | Motorola Mobility, Inc. | Distributed architecture and methods for broadcast/multicast service |
| US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
| EP1847278A1 (en) * | 2006-04-13 | 2007-10-24 | Camlog Biotechnologies AG | Bio-dissolvable salt coatings of implants for the protection against organic impurities |
| US20070255086A1 (en) * | 2006-04-26 | 2007-11-01 | Nehls Robert J | Medical Device Including Magnetic Particles |
| US9265865B2 (en) * | 2006-06-30 | 2016-02-23 | Boston Scientific Scimed, Inc. | Stent having time-release indicator |
| JP2009545407A (en) | 2006-08-02 | 2009-12-24 | ボストン サイエンティフィック サイムド，インコーポレイテッド | End prosthesis with 3D decomposition control |
| JP2010503485A (en) | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Medical device and method for manufacturing the same |
| ATE517590T1 (en) | 2006-09-15 | 2011-08-15 | Boston Scient Ltd | BIOLOGICALLY ERODABLE ENDOPROTHESES |
| JP2010503490A (en) | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Endoprosthesis with adjustable surface features |
| US8808726B2 (en) | 2006-09-15 | 2014-08-19 | Boston Scientific Scimed. Inc. | Bioerodible endoprostheses and methods of making the same |
| ES2368125T3 (en) | 2006-09-15 | 2011-11-14 | Boston Scientific Scimed, Inc. | BIOEROSIONABLE ENDOPROOTHESIS WITH BIOESTABLE INORGANIC LAYERS. |
| US8002821B2 (en) | 2006-09-18 | 2011-08-23 | Boston Scientific Scimed, Inc. | Bioerodible metallic ENDOPROSTHESES |
| DE102006048819A1 (en) * | 2006-10-10 | 2008-04-17 | NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen | Device with a basic body |
| US20090281584A1 (en) * | 2006-12-20 | 2009-11-12 | Andreas Blomqvist | Implantable sensor arrangement |
| ATE488259T1 (en) | 2006-12-28 | 2010-12-15 | Boston Scient Ltd | BIOERODIBLE ENDOPROTHES AND PRODUCTION METHODS THEREOF |
| US8000810B2 (en) * | 2007-03-20 | 2011-08-16 | Cardiac Pacemakers, Inc. | Systems and methods for transvenous lead implantation |
| US20090024197A1 (en) * | 2007-07-18 | 2009-01-22 | Cardiac Pacemakers, Inc. | Elution control via geometric features of an implantable substance matrix |
| US8070798B2 (en) | 2007-07-20 | 2011-12-06 | Josiah Wilcox | Drug eluting medical device and method |
| US8728101B2 (en) * | 2007-08-21 | 2014-05-20 | Castlewood Surgical, Inc. | System and method for providing an obturator for enhanced directional capabilities in a vascular environment |
| US8486094B2 (en) * | 2007-08-21 | 2013-07-16 | Castlewood Surgical, Inc. | System and method for providing an obturator for enhanced directional capabilities in a vascular environment |
| US20090093825A1 (en) * | 2007-08-21 | 2009-04-09 | Castlewood Surgical, Inc. | System and Method for Providing a Coil Element in a Vascular Environment |
| WO2009025597A1 (en) * | 2007-08-22 | 2009-02-26 | St. Jude Medical Ab | Medical lead with a cover |
| US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
| US8109908B1 (en) * | 2008-01-22 | 2012-02-07 | Greatbatch Ltd. | Biodegradable shroud for a dilator/sheath assembly |
| US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
| US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
| US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
| US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
| US8527068B2 (en) | 2009-02-02 | 2013-09-03 | Nanostim, Inc. | Leadless cardiac pacemaker with secondary fixation capability |
| EP2403546A2 (en) | 2009-03-02 | 2012-01-11 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
| WO2011065881A1 (en) * | 2009-11-30 | 2011-06-03 | St. Jude Medical Ab | A medical implantable lead with fixation detection |
| US8740970B2 (en) * | 2009-12-02 | 2014-06-03 | Castlewood Surgical, Inc. | System and method for attaching a vessel in a vascular environment |
| US8668732B2 (en) | 2010-03-23 | 2014-03-11 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
| US9060692B2 (en) | 2010-10-12 | 2015-06-23 | Pacesetter, Inc. | Temperature sensor for a leadless cardiac pacemaker |
| CN103249452A (en) | 2010-10-12 | 2013-08-14 | 内诺斯蒂姆股份有限公司 | Temperature sensor for a leadless cardiac pacemaker |
| US9020611B2 (en) | 2010-10-13 | 2015-04-28 | Pacesetter, Inc. | Leadless cardiac pacemaker with anti-unscrewing feature |
| EP2651502B1 (en) | 2010-12-13 | 2016-11-09 | Pacesetter, Inc. | Pacemaker retrieval systems |
| EP2651494B1 (en) | 2010-12-13 | 2017-02-15 | Pacesetter, Inc. | Delivery catheter |
| JP2014501584A (en) | 2010-12-20 | 2014-01-23 | ナノスティム・インコーポレイテッド | Leadless space maker with radial fixing mechanism |
| EP2476456A1 (en) * | 2011-01-13 | 2012-07-18 | BIOTRONIK SE & Co. KG | Self-Dissolving Electrode or Probe Implant |
| WO2013067496A2 (en) | 2011-11-04 | 2013-05-10 | Nanostim, Inc. | Leadless cardiac pacemaker with integral battery and redundant welds |
| US9802054B2 (en) | 2012-08-01 | 2017-10-31 | Pacesetter, Inc. | Biostimulator circuit with flying cell |
| AU2013331359B2 (en) | 2012-10-16 | 2018-04-19 | Boston Scientific Scimed, Inc. | Tools and methods for treatment of pelvic conditions |
| WO2016100948A1 (en) | 2014-12-19 | 2016-06-23 | Cardiac Pacemakers, Inc. | Medical lead anchoring |
| CN108472483A (en) * | 2015-11-30 | 2018-08-31 | 神经毫微股份公司 | Avoid the microelectrode of bleeding |
| DE102016105845A1 (en) | 2016-03-31 | 2017-10-05 | Biotronik Se & Co. Kg | Electrode head for a pacemaker or defibrillator electrode |
| EP3308832A1 (en) * | 2016-10-14 | 2018-04-18 | BIOTRONIK SE & Co. KG | Electric implant or implant system |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3750650A (en) * | 1970-12-15 | 1973-08-07 | Hewlett Packard Gmbh | Double spiral electrode for intra-cavity attachment |
| US3736939A (en) * | 1972-01-07 | 1973-06-05 | Kendall & Co | Balloon catheter with soluble tip |
| US3844292A (en) * | 1972-06-09 | 1974-10-29 | Medtronic Inc | Intravascular lead assembly |
| US3974834A (en) * | 1975-04-23 | 1976-08-17 | Medtronic, Inc. | Body-implantable lead |
| US4046151A (en) * | 1976-04-30 | 1977-09-06 | Medtronic, Inc. | Body implantable lead with stiffening stylet |
| US4106512A (en) * | 1976-12-16 | 1978-08-15 | Medtronic, Inc. | Transvenously implantable lead |
| US4180080A (en) * | 1977-10-03 | 1979-12-25 | Hewlett-Packard Company | Electrode assembly for sensing heart activity |
| US4149528A (en) * | 1977-10-03 | 1979-04-17 | Hewlett-Packard Company | Electrode assembly for sensing heart activity |
| US4146036A (en) * | 1977-10-06 | 1979-03-27 | Medtronic, Inc. | Body-implantable lead with protector for tissue securing means |
| US4217913A (en) * | 1977-10-10 | 1980-08-19 | Medtronic, Inc. | Body-implantable lead with protected, extendable tissue securing means |
| DK141034B (en) * | 1977-11-22 | 1979-12-31 | C C Hansen | ELECTRODE FOR INSERTING IN THE SNAIL OF THE CITY (COCHLEA) |
| FR2423231A1 (en) * | 1978-04-19 | 1979-11-16 | Synthelabo | ENDOCAVITY CARDIAC STIMULATION PROBE |
| US4207903A (en) * | 1978-04-28 | 1980-06-17 | Medtronic, Inc. | Device for screwing body tissue electrode into body tissue |
| US4282885A (en) * | 1978-08-21 | 1981-08-11 | Bisping Hans Juergen | Electrode for implantation in the heart |
| US4209019A (en) * | 1979-01-05 | 1980-06-24 | Medtronic, Inc. | Stylet insertion guide and rotation control device for use with body implantable lead |
| SU908373A1 (en) * | 1980-01-11 | 1982-02-28 | Каунасский Медицинский Институт | Method of introducing endocardial electrode |
| US4381013A (en) * | 1981-03-19 | 1983-04-26 | Medtronic, Inc. | "J" Stylet wire |
| US4452254A (en) * | 1981-07-13 | 1984-06-05 | Goldberg Edward M | Cardiac electrode and method for installing same |
| US4628944A (en) * | 1982-02-08 | 1986-12-16 | Cordis Corporation | Cardiac pacing lead with biodegradable fixation structure |
| JPS58185170A (en) * | 1982-02-08 | 1983-10-28 | コーディス、リーズ、インコーポレイテッド | Cardiac pacing lead body having living body decomposable fixing means |
| US4463765A (en) * | 1982-08-30 | 1984-08-07 | Cordis Corporation | Screw-in pacing lead assembly |
| US4576142A (en) * | 1982-11-19 | 1986-03-18 | Peter Schiff | Percutaneous intra-aortic balloon and method for using same |
| US4550737A (en) * | 1983-10-12 | 1985-11-05 | Peter Osypka | Intravenously implantable electrode lead for use with cardiac pacemakers |
-
1987
- 1987-04-13 US US07/037,684 patent/US4827940A/en not_active Expired - Lifetime
-
1988
- 1988-12-13 CA CA000585746A patent/CA1326700C/en not_active Expired - Fee Related
- 1988-12-15 EP EP88311860A patent/EP0337035B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0337035A1 (en) | 1989-10-18 |
| US4827940A (en) | 1989-05-09 |
| EP0337035B1 (en) | 1993-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1326700C (en) | Soluble covering for cardiac pacing electrode | |
| US4876109A (en) | Soluble covering for cardiac pacing electrode | |
| US5473812A (en) | Method of manufacturing medical electrical lead having a torque indicator | |
| US5908447A (en) | Breakaway structure for body implantable medical device | |
| US7177704B2 (en) | Pacing method and apparatus | |
| US5807399A (en) | Method for removal of chronically implanted leads and leads optimized for use therewith | |
| US5531783A (en) | Pacing lead with x-ray visible soluble covering and method of inserting same into a patient's heart | |
| US5755762A (en) | Medical lead and method of making and using | |
| US5951597A (en) | Coronary sinus lead having expandable matrix anchor | |
| US6711443B2 (en) | Implantable coronary sinus lead and method of implant | |
| US5531780A (en) | Implantable stimulation lead having an advanceable therapeutic drug delivery system | |
| EP0977613B1 (en) | Left ventricular access lead for heart failure pacing | |
| US5931864A (en) | Coronary venous lead having fixation mechanism | |
| EP0939658B1 (en) | Medical electrical lead | |
| US6136021A (en) | Expandable electrode for coronary venous leads | |
| US6738674B2 (en) | Implantable coronary sinus lead with mapping capabilities | |
| US6078840A (en) | Medical electrical lead having improved fixation | |
| US7079902B2 (en) | System for promoting selective tissue in-growth for an implantable medical device | |
| US4258724A (en) | Endocavitary cardiac stimulation probe | |
| EP1070515B1 (en) | Implantable electrode lead | |
| JPH09508539A (en) | Floating myocardial electrode for implantable pulse generator | |
| CA2104861A1 (en) | Removable endocardial lead | |
| US6091978A (en) | Removable cap for tissue-insertable connections | |
| US6473633B1 (en) | Removable cap for tissue-insertable connections | |
| JPH0412991B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |